Strength builds in unquoted portfolio
A strong year for Imperial Innovations (LON:IVO) was defined by continued 3 November 2016 momentum in the unquoted portfolio, a strengthened balance sheet and the extension of connections to university IP. The net portfolio value (£335.1m) grew over FY15 (£327.2m), but was affected by the disappointing Phase III Cat SPIRE results from Circassia. Multiple inflection points approach in FY17 and IVO is in a strong position to continue to drive value across its entire portfolio.
Strong growth in unquoted portfolio
Six major funding rounds were achieved in FY16 raising £168.0m in total, with IVO committing £42.2m (25%). The growing number of collaborations and technical partnerships continues to provide validation for the unquoted portfolio as the companies progress towards major near-term inflection points. The continued diversification of the portfolio, with the increased number and size of investments in ICT/digital and engineering & materials, provides alternative opportunities for future growth outside the traditional investments in healthcare.
To read the entire report Please click on the pdf File Below